Red Orbit (Free subscription) | 15/08/2008
By Brice Wallace Deseret News A biopharmaceutical giant will expand its operations in Utah after getting a financial incentive from the state. The Governor's Office of Economic Development Board on Thursday approved a nearly $1.7 million tax credit for Cephalon Inc.
Boston Globe (Free subscription) | 12/08/2008
Federal regulators warned doctors Tuesday about severe skin reactions seen in patients taking an injectable treatment for alcoholism made by Alkermes Inc. and marketed by Cephalon Inc.
The Philadelphia Business Journal (Free subscription) | 12/08/2008
A drug to treat alcoholism developed by Alkermes Inc. has caused blood clots, swelling, abscesses, cell death and other adverse reactions in nearly 200 cases, according to a warning for health-care professionals issued Tuesday by the Food and Drug Administration. (ALKS) (CEPH)
Business Wire (Free subscription) | 12/08/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting
Market Wire - Investment Opinion (Free subscription) | 07/08/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Universal Detection Technology (OTCBB: UNDT), Cephalon, Inc. (NASDAQ: CEPH) and Applied Biosystems Inc. (NYSE: ABI).
GuruFocus Updates (Free subscription) | 05/08/2008
While a lot of value managers have hard times, Rick Aster avoided big losses. His value fund performed better than the market by about 4.5%, and his growth fund matched the market. These are his buys and sells during the second quarter. Richard Aster Jr owns 136 stocks with a total value of $2.76 billion.
Medical,Health News and Articles (Free subscription) | 31/07/2008
Medical Patent News Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Cephalon, Inc. in connection with its Fentora(R) Tablets (fentanyl citrate buccal tablets), equivalent [...]
Seeking Alpha (Free subscription) | 30/07/2008
Cephalon, Inc. (CEPH) Q2 FY08 Earnings Call Complete Story ยป
The Street (Free subscription) | 30/07/2008
The biotech company also raises guidance for the year.
Market Watch (Free subscription) | 29/07/2008
SAN FRANCISCO (MarketWatch) -- Cephalon Inc. said late Tuesday that it swung to a second-quarter profit of $60.1 million, or 80 cents a share, from a loss of $4.3 million, or 6 cents a share, in the year-ago period. Excluding one-time items, the company said it would have reported earnings of $1.13 a share in the latest quarter. Revenue rose to $492.7 million from $447.2 million last year. Analysts...
PR News Wire (Free subscription) | 29/07/2008
TREANDA and AMRIX Off to Strong Starts Cephalon Advances NUVIGIL Launch to 2009 Maintains 2008 Earnings Guidance Despite New Spending for Pre-Launch NUVIGIL Activity and Increased AMRIX Investment FRAZER, Pa., July 29 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2008 sales of $485.0 million, compared to sales of $435.2 million for the second quarter 2007...
The Philadelphia Business Journal (Free subscription) | 25/07/2008
Cephalon Inc. said Thursday night it filed a patent infringement lawsuit earlier this week against Barr Pharmaceuticals Inc. and its wholly owned subsidiary, Barr Laboratories Inc., regarding Cephalon's Fentora cancer pain drug. (CEPH) (BRL)
Market Wire - Investment Opinion (Free subscription) | 17/07/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), Bristol-Myers Squibb Company (NYSE: BMY), Cephalon, Inc. (NASDAQ: CEPH) and Oracle Corporation (NASDAQ: ORCL).
Business Wire (Free subscription) | 17/07/2008
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Canadian Solar (Nasdaq: CSIQ) as the Bull of the Day and The Corp. Executive Board (Nasdaq: EXBD) as the Bear of the
Medical News Today (Free subscription) | 16/07/2008
Cephalon, Inc. (Nasdaq: CEPH) announced that in a phase 2 study published online in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab.
